VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia.
D000293:Adolescent; D000328:Adult; D001772:Blood Cell Count; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000627:therapeutic use*
D003561:Cytarabine; D013713:Teniposide; D015122:Mercaptopurine; D011034:Podophyllotoxin; D008727:Methotrexate